{
    "clinical_study": {
        "@rank": "70592", 
        "acronym": "PEAKS", 
        "arm_group": [
            {
                "arm_group_label": "Patients with type 2 diabetes mellitus"
            }, 
            {
                "arm_group_label": "Normoglycemic individuals", 
                "description": "Control group"
            }
        ], 
        "biospec_descr": {
            "textblock": "Blood will be collected"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "Impaired uptake of glucose by skeletal muscle is a key feature of type 2 diabetes mellitus.\n      It is unclear to what extent impaired insulin uptake from capillaries into skeletal muscle\n      interstitium plays a role in this process.\n\n      We hypothesize that impaired uptake of insulin from capillaries into skeletal muscle\n      interstitium is involved in impaired glucose uptake by skeletal muscle in type 2 diabetes\n      mellitus."
        }, 
        "brief_title": "Peripheral Insulin Uptake in Type 2 Diabetes Mellitus and in Non-Diabetic Individuals", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria for all participants:\n\n          -  written informed consent\n\n          -  hemodynamically stable with a systolic blood pressure > 100 mmHg\n\n          -  medical need to undergo a CAG procedure as determined by cardiologist\n\n        Exclusion criteria for all participants:\n\n          -  ongoing myocardial infarction as determined from elevated cardiac markers\n\n          -  participation in an investigational trial within 90 days prior to present study\n\n          -  donation of blood (> 100 mL) within 90 days prior to present study\n\n          -  serious mental impairment or language problems i.e. preventing to understand the\n             study protocol/aim\n\n          -  Use or recent use (within 3 months of study participation) of oral glucocorticoids\n\n        Inclusion criteria for non-diabetic individuals:\n\n          -  30 years \u2264 age \u2264 80 years (extremes included)\n\n          -  fasting glucose level of < 7.0 mmol/L and HbA1C < 6.5% (= < 48 mmol/mol)\n\n        Exclusion criteria for non-diabetic individuals:\n\n        - known T2DM/use of glucose-lowering medication\n\n        Inclusion criteria for T2DM patients:\n\n          -  30 years \u2264 age \u2264 80 years (extremes included)\n\n          -  fasting glucose level of > 7.0 mmol/L, or HbA1C > 6.5 (= > 48 mmol/mol) or known T2DM\n\n        Exclusion criteria for T2DM patients:\n\n        - treatment with insulin preparations"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "30 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "50 subjects with T2DM and 50 nondiabetic individuals"
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02031341", 
            "org_study_id": "KGINTDVR001"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Haarlem", 
                    "country": "Netherlands", 
                    "zip": "2023 KT"
                }, 
                "name": "Kennemer Gasthuis"
            }
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_groups": "2", 
        "official_title": "Peripheral Insulin Uptake in Type 2 Diabetes Mellitus and in Non-Diabetic Individuals", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "During a single measure (thus cross-sectional) the primary endpoint will be measured.", 
            "measure": "Fore-arm insulin uptake measured as ([A]-[V]) x F in pmol/min where A = arterial insulin concentrations, V= venous insulin concentrations, F = fore arm plasma flow;", 
            "safety_issue": "No", 
            "time_frame": "Baseline"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02031341"
        }, 
        "responsible_party": {
            "investigator_affiliation": "VU University Medical Center", 
            "investigator_full_name": "D van Raalte", 
            "investigator_title": "MD PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "VU University Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "VU University Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}